Metabolic & Obesity Deal Benchmarks
GLP-1, diabetes, NASH/MASH, and obesity drug deal benchmarks. Benchmarks derived from 158 verified transactions.
158
Total Deals
$317M
Avg Upfront
7
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
82
license
33
acquisition
28
collaboration
1
option
6
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Structure Therapeutics → Roche oral GLP-1 patents | license | $100M | — | Mar 2026 |
Structure Therapeutics → Roche CT-996 | license | $100M | — | Mar 2026 |
Structure Therapeutics → Roche CT-996 | license | $100M | — | Mar 2026 |
Structure Therapeutics → Roche oral GLP-1 assets | license | $100M | — | Mar 2026 |
Suzhou Ribo Life Sciences → Madrigal Pharmaceuticals | license | $60M | $4.5B | Feb 2026 |
Suzhou Ribo Life Science Co. Ltd. and Ribocure Pharmaceuticals AB → Madrigal Pharmaceuticals, Inc. | license | $60M | $4.5B | Feb 2026 |
CSPC Pharmaceutical Group → AstraZeneca | license | $1.2B | $18.5B | Jan 2026 |
CSPC Pharmaceutical → AstraZeneca SYH2082 | license | $1.2B | $18.5B | Jan 2026 |
Structure Therapeutics → Roche CT-996 | license | $100M | — | Jan 2026 |
YaoPharma → Pfizer YP05002 | license | $150M | $2.1B | Dec 2025 |
Benchmark Your Metabolic & Obesity Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 158 verified metabolic & obesity transactions.
Run Metabolic & Obesity Benchmark